News
Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback